AEON Biopharma, Inc.

Q2 FY2026 EarningsQ2 FY2026 results showed a GAAP EPS of -$0.02, significantly beating the consensus estimate of -$0.12. While revenue remained at zero as expected for a clinical-stage biotech, the operating loss of -$5.9M was slightly wider than the -$5.8M EBIT consensus due to a 176% YoY surge in R&D expenses. A $15.3M financing completed in July extends the cash runway into Q1 2027, supporting upcoming BPD Type 2b regulatory milestones for ABP-450.